CARGO Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • CARGO Therapeutics's estimated annual revenue is currently $28.9M per year.(i)
  • CARGO Therapeutics's estimated revenue per employee is $193,750

Employee Data

  • CARGO Therapeutics has 149 Employees.(i)
  • CARGO Therapeutics grew their employee count by 107% last year.

CARGO Therapeutics's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
President and CEOReveal Email/Phone
3
Chief Legal OfficerReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Chief Financial Officer and Chief Business OfficerReveal Email/Phone
6
Chief Technical OfficerReveal Email/Phone
7
Chief Medical OfficerReveal Email/Phone
8
CTOReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is CARGO Therapeutics?

CARGO Therapeutics, formerly Syncopation Life Sciences, is advancing a new generation of adoptive cell therapies for cancers. Our cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently available Chimeric Antigen Receptor T-cell (CAR T) therapies. Despite the advances made by existing autologous CAR T therapies, these treatments are only curative for less than half of all cancer patients, and therapeutic failure, resistance, and relapse are common. In addition, far too many patients are unable to access these potentially curative therapies due to barriers, including manufacturing, supply, time, and reimbursement challenges. CARGO is actively working to address these barriers with novel solutions that address the problems of resistance and access. Through smarter science, CARGO is developing and delivering CAR T-cell therapies to cure more patients. Focused on the delivery of complex therapeutic cargo, we enable the multiplex engineering necessary to overcome multiple mechanisms of tumor resistance, to counter inhibition by solid tumors, and in the allogeneic setting to evade immune rejection. From research to manufacturing to clinical care, we at CARGO aspire to disrupt the status quo to overcome resistance and maximize access to curative therapeutics.

keywords:N/A

N/A

Total Funding

149

Number of Employees

$28.9M

Revenue (est)

107%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.9M14910%N/A
#2
$20.8M14914%$1.3B
#3
$33.6M149N/AN/A
#4
$45.1M15262%N/A
#5
$24.2M152N/AN/A